A biopharmaceutical innovator developing proprietary small molecule drugs for chronic conditions including fibrosis and neurodegeneration with a strong cash position to fund R&D.
Investors should consider this stock due to the company's turnaround in profitability, evidenced by a net income of $124.5M and strong operating cash flows that support its innovative pipeline. The presence of multiple proprietary assets in lucrative therapeutic areas like fibrosis offers significant upside potential if key trials succeed and market adoption accelerates. With substantial cash reserves and minimal debt repayments required, the company is well-positioned to navigate clinical uncertainties and pursue strategic growth opportunities.
The volatile revenue trend, dropping from $196.2M in 2022 to $131.3M in 2023 before recovering, suggests potential instability in product sales or market dynamics that warrants caution. High operating expenses of $227.1M relative to revenue indicate ongoing pressure on margins as the company invests heavily in R&D and commercialization efforts. Dependence on external partnerships and licensing deals introduces execution risk, particularly if key collaborators face delays or regulatory hurdles.
Ligand Pharmaceuticals Inc. is a global biopharmaceutical company specializing in developing proprietary small molecule drugs for chronic diseases such as fibrosis, neurodegeneration, and cancer. The company serves markets across the United States, Europe, Asia-Pacific, Latin America, and the Middle East through its diverse portfolio of therapies targeting unmet medical needs. Its revenue streams are primarily derived from sales of branded pharmaceutical products under exclusive licenses and strategic collaborations.
The company reported a significant improvement in financial performance, with revenue climbing to $268.1M in 2025 compared to $196.2M in 2022, driven by strong product sales and successful collaborations. Net income turned highly positive at $124.5M for the latest period, contrasting sharply with the $-33.4M loss in 2022, indicating effective cost management and operational efficiency gains. Cash flow from operations of $49.4M supports continued investment in R&D totaling $81.2M while maintaining a healthy cash reserve.
The global biopharmaceutical industry is rapidly evolving with a focus on personalized medicine and treatments for chronic diseases affecting millions of patients worldwide. Companies are increasingly investing in novel drug mechanisms to address unmet needs in areas like fibrosis and neurodegeneration where traditional therapies have limited efficacy. Regulatory landscapes remain stringent, requiring substantial capital investment and long development timelines to bring new drugs to market successfully.
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Revenue | $196.2M | $131.3M | $167.1M | $268.1M |
| Cost of Revenue | $0 | $0 | $0 | $0 |
| Gross Profit | $196.2M | $131.3M | $167.1M | $268.1M |
| Operating Expenses | $193.2M | $119.4M | $189.7M | $227.1M |
| Operating Income | $3.0M | $11.9M | $-22.6M | $41.0M |
| R&D | $36.1M | $24.5M | $21.4M | $81.2M |
| G&A | $70.1M | $52.8M | $78.7M | $92.4M |
| Stock-Based Comp | $60.3M | $25.7M | $41.1M | $46.8M |
| D&A | $51.5M | $36.5M | $35.2M | $33.8M |
| Depreciation | $3.8M | $2.9M | $2.3M | $1.0M |
| Other OpEx | $87.1M | $42.0M | $89.7M | $53.5M |
| Non-Operating Income | $33.0M | $51.7M | $25.1M | $118.0M |
| Interest Expense | $1.8M | $656.0K | — | — |
| Interest Income | $2.0M | $7.7M | $8.1M | $13.7M |
| Pre-Tax Income | $36.0M | $63.7M | $2.5M | $159.0M |
| Income Tax | $41.2M | $9.8M | $6.5M | $34.5M |
| Continuing Ops | $-5.2M | $53.8M | $-4.0M | $124.5M |
| Discontinued Ops | $-28.1M | $-1.7M | $0 | $0 |
| Net Income | $-33.4M | $52.2M | $-4.0M | $124.5M |
| Minority Interest | $0 | $0 | $0 | $0 |
| Net to Common | $-33.4M | $52.2M | $-4.0M | $124.5M |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Current Assets | $263.6M | $237.4M | $331.6M | $832.3M |
| Cash & Equivalents | $45.0M | $23.0M | $72.3M | $174.9M |
| Marketable Securities | $166.9M | $147.4M | $183.9M | $558.6M |
| Accounts Receivable | $30.4M | $32.9M | $38.4M | $59.6M |
| Inventory | $13.3M | $24.0M | $14.1M | $9.1M |
| Other Current Assets | $8.0M | $10.2M | $22.9M | $30.0M |
| Long-Term Assets | $499.1M | $549.8M | $610.2M | $728.4M |
| PP&E (Net) | $12.5M | $15.6M | $15.1M | $3.6M |
| Intangibles | $342.5M | $299.6M | $266.6M | $225.4M |
| Goodwill | $105.7M | $103.4M | $105.2M | $101.5M |
| Operating Leases | $10.9M | $6.1M | $6.9M | $5.2M |
| Other LT Assets | $27.5M | $112.5M | $216.3M | $346.2M |
| Total Assets | $762.7M | $787.2M | $941.8M | $1.56B |
| Current Liabilities | $98.8M | $16.8M | $37.1M | $37.4M |
| Accounts Payable | $5.3M | $2.4M | $5.2M | $3.2M |
| Current Leases | $670.0K | $403.0K | $1.3M | $1.1M |
| Deferred Revenue | $355.0K | $1.2M | $1.3M | $621.0K |
| Other Current Liab | $76.8M | $263.0K | $1.4M | $1.0M |
| Long-Term Liabilities | $66.4M | $69.5M | $74.2M | $506.0M |
| LT Operating Leases | $10.3M | $5.8M | $5.8M | $4.2M |
| Other LT Liab | $56.0M | $50.1M | $52.5M | $501.8M |
| Total Liabilities | $165.2M | $86.3M | $111.3M | $543.4M |
| Shareholders' Equity | $597.5M | $700.9M | $830.4M | $1.02B |
| Paid-In Capital | $147.6M | $198.7M | $337.4M | $400.6M |
| Retained Earnings | $450.9M | $503.0M | $499.0M | $608.1M |
| AOCI | $-984.0K | $-817.0K | $-5.9M | $8.5M |
| Total L&E | $762.7M | $787.2M | $941.8M | $1.56B |
| Metric | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|
| Net Income (CFO) | $-33.4M | $52.2M | $-4.0M | $124.5M |
| Non-Cash Adjustments | $276.9M | $-17.8M | $79.4M | $-75.7M |
| Working Capital Changes | $-105.6M | $15.2M | $21.6M | $589.0K |
| Cash from Operations | $137.8M | $49.6M | $97.0M | $49.4M |
| Capital Expenditures | $17.9M | $3.5M | $1.8M | $452.0K |
| Cash from Investing | $163.6M | $-11.7M | $-143.7M | $-377.3M |
| Debt Repayments | $260.9M | $76.9M | $0 | $0 |
| Share Buybacks | $0 | — | — | $15.0M |
| Cash from Financing | $-276.0M | $-59.9M | $97.1M | $428.2M |
| FX Effect | $0 | $0 | $-1.2M | $2.4M |
| Net Change in Cash | $25.5M | $-22.1M | $49.4M | $102.6M |
| Beginning Cash | $19.5M | $45.0M | $23.0M | $72.3M |
| Ending Cash | $45.0M | $23.0M | $72.3M | $174.9M |
Primary revenue is generated through the sale of proprietary small molecule drugs targeting indications like fibrosis, neurodegeneration, and oncology. Secondary streams include royalties from exclusive licensing agreements with partners in various therapeutic areas. Additional income comes from strategic collaborations that provide upfront payments and milestone-based revenues for new drug candidates.
Clinical trial failures or regulatory setbacks could halt development of key drug candidates, significantly impacting future revenue projections. Intense competition from major pharmaceutical players and biosimilar entrants may erode market share and pricing power for existing products. Potential shifts in healthcare reimbursement policies or patent expirations could reduce profitability and shorten the commercial life of current assets.
The company possesses a robust pipeline of proprietary small molecule drugs targeting high-need chronic diseases with differentiated mechanisms of action. A strong balance sheet with over $174M in cash provides significant flexibility to fund research, development, and strategic acquisitions without immediate reliance on equity dilution. Established global commercial capabilities allow for efficient market penetration in key therapeutic areas like fibrosis and neurodegeneration.
Not financial advice. All content is for informational purposes only. Data may contain errors. Consult a qualified financial advisor before making investment decisions.